# Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)

> **NCT05872685** · PHASE2 · RECRUITING · sponsor: **Yu jiren** · enrollment: 314 (estimated)

## Conditions studied

- Adenocarcinoma of the Stomach
- Adenocarcinoma of Esophagogastric Junction
- Proficient Mismatch Repair

## Interventions

- **DRUG:** S1
- **DRUG:** Oxaliplatin
- **DRUG:** Serplulimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05872685
- **Lead sponsor:** Yu jiren
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-24
- **Primary completion:** 2026-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 314 (ESTIMATED)
- **Last updated:** 2024-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05872685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05872685, "Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05872685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*